Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:acquired_by |
gptkb:Daiichi_Sankyo
|
| gptkbp:acquisition |
Acquired by Daiichi Sankyo in 2008
|
| gptkbp:awards |
various industry awards
Quality awards Innovation awards Best Employer awards |
| gptkbp:challenges |
patent expirations
market access barriers regulatory compliance issues pricing pressures competition from local and global firms |
| gptkbp:employees |
over 10,000
|
| gptkbp:founded |
gptkb:1961
|
| gptkbp:founder |
gptkb:B._D._Sanghvi
|
| gptkbp:future_plans |
strengthening global partnerships
development of new products enhancing manufacturing capabilities investment in R& D expansion in new markets |
| gptkbp:headquarters |
gptkb:Gurgaon,_India
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ranbaxy Laboratories
|
| gptkbp:market_share |
growing in emerging markets
significant in India expanding in the US |
| gptkbp:notable_products |
gptkb:Metformin
gptkb:Ciprofloxacin gptkb:Omeprazole Atorvastatin Simvastatin |
| gptkbp:operates_in |
over 150 countries
|
| gptkbp:partnerships |
collaborated with various global companies
|
| gptkbp:products |
generic drugs
|
| gptkbp:regulatory_compliance |
FDA warning letters
settled lawsuits |
| gptkbp:research_and_development |
focus on complex generics
focus on biosimilars focus on generics |
| gptkbp:revenue |
$1.5 billion (2013)
|
| gptkbp:social_responsibility |
education programs
healthcare initiatives community development projects environmental sustainability efforts |
| gptkbp:subsidiary |
gptkb:Ranbaxy_USA_Inc.
gptkb:Ranbaxy_Pharmaceuticals_Inc. gptkb:Ranbaxy_(UK)_Limited gptkb:Ranbaxy_Laboratories_(Malaysia)_Sdn_Bhd gptkb:Ranbaxy_(South_Africa)_(Pty)_Ltd. |
| gptkbp:website |
www.ranbaxy.com
|
| gptkbp:bfsParent |
gptkb:Daiichi_Sankyo
gptkb:Sun_Pharmaceutical_Industries |
| gptkbp:bfsLayer |
5
|